Connect with us


How CBD could help tackle opioid addiction



“Opioids are a huge driver of overdose deaths in the US." - Sohail R. Zaidi, President of ANANDA.

A new study will explore the effect of a unique CBD technology on reducing opioid consumption in chronic pain patients.

US biotech pharma company, ANANDA have announced a second clinical trial to evaluate the effect of cannabidiol in its unique delivery technology, on opioid sparing in participants with chronic pain syndromes.

An Investigational New Drug (IND) application has been approved by the US Food and Drug Administration (FDA) for the trial, which will be led by researchers at NYU Grossman School of Medicine, using ANANDA’s proprietary Liquid Structure™ CBD.

Pre-clinical and initial clinical studies show ANANDA’s Liquid Structure technology enhances the effectiveness and stability of CBD. 

This innovation creates new potential to facilitate voluntary opioid sparing and the ability to reduce opioid intake in patients being treated for chronic pain.

“Approval of a second clinical trial with this world-renowned institution further advances applications for CBD in ANANDA’s patented delivery technology in an area that could positively impact the lives of a large number of people suffering from opioid addiction,” said Sohail R. Zaidi, ANANDA’s President.

“Opioids are a huge driver of overdose deaths in the US and non-addictive therapy is a significant unmet need.”

The trial is being conducted at NYU Grossman School of Medicine led by principal investigator Stephen Ross, MD, Associate Professor Department of Psychiatry and Director NYU Addictive Disorders and Experimental Therapeutics Research Laboratory.

 Funding for this trial is from National Institute on Drug Abuse (NIDA), with additional support from ANANDA Scientific.

“Expanding research on therapeutic alternatives to opioid pharmacotherapies for chronic pain disorders, such as CBD medicinal products, is critical to reversing the opioid epidemic,” said Dr Ross.

“ANANDA’s commitment to safe, efficacious, high-quality products, paired with their groundbreaking delivery technology, creates tremendous opportunity for the development of evidence-based CBD medicinal products to reduce opioid intake and pain. 

“We look forward to collaborating with ANANDA on this important clinical work.”

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister titles, Cannabis Wealth and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag


Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2023 PP Intelligence Ltd.